BB-Cl-Amidine is a Novel Therapeutic for Canine and Feline Mammary Cancer via Activation of the Endoplasmic Reticulum Stress Pathway. BB-Cl-Amidine is a modified version of Cl-amidine that retains the functional components but possesses a C-terminal benzimidazole group designed to limit proteolysis of the C-terminal amide. BB-CLA reduced viability and tumorigenicity of canine and feline mammary cancer cell lines in vitro. BB-CLA activates the endoplasmic reticulum stress pathway in these cells by downregulating 78 kDa Glucose-regulated Protein (GRP78), a potential target in breast cancer for molecular therapy, and upregulating the downstream target gene DNA Damage Inducible Transcript 3 (DDIT3).
MedKoo Cat#: 408076
Name: BB-Cl-Amidine
CAS#: 1802637-39-3
Chemical Formula: C26H26ClN5O
Exact Mass: 459.1826
Molecular Weight: 459.98
Elemental Analysis: C, 67.89; H, 5.70; Cl, 7.71; N, 15.23; O, 3.48
| Solvent | mg/mL | mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 76.3 | 165.94 | |
| DMF | 20.0 | 43.48 | |
| Water | 70.0 | 152.18 | |
| Ethanol | 54.5 | 118.48 | |
| Ethanol:PBS (pH 7.2) (1:1) | 0.5 | 1.09 |
The following data is based on the product molecular weight 459.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
